The US P2Y12 inhibitors market is an integral part of the cardiovascular therapeutics segment. P2Y12 inhibitors, commonly known as antiplatelet drugs, play a key role in preventing blood clots and reducing ischemic events in patients undergoing angioplasty or stenting procedures. These drugs work by selectively and reversibly blocking the adenosine diphosphate receptor P2Y12 found on platelet surfaces, thereby hampering platelet activation and aggregation. Wide usage of P2Y12 inhibitors for post cardiovascular intervention, rapid revascularization, and reducing cardiovascular mortality has boosted the US market.
The Global US P2Y12 inhibitors Market is estimated to be valued at US$ 267.73 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the US P2Y12 inhibitors are Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation.
The growing demand for P2Y12 inhibitors is attributed to the rise in cardiovascular disorders within the United States. Also, the increasing geriatric population which is more prone to heart ailments has further augmented the need for P2Y12 inhibitors.
North America dominates the Global P2Y12 Inhibitors Market Share owing to the rising prevalence of coronary artery diseases in the region. Additionally, the availability of advanced cardiac facilities and favorable reimbursement policies are fueling the market growth.
Market Key Trends
One of the key trends witnessed in the US P2Y12 inhibitors market is the growing adoption of novel oral antiplatelet drugs over traditional ones. While clopidogrel was the dominant oral drug till some years back, newer agents like ticagrelor and cangrelor have gained significant popularity in recent times owing to their improved efficacy and reduced side effects. This shift towards novel oral drugs has positively impacted the overall market revenues.
Porter’s Analysis
Threat of new entrants: The U.S. P2Y12 inhibitors market requires high R&D investments and regulatory approvals pose a barrier to entry.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over smaller buyers in this market.
Bargaining power of suppliers: The presence of several ingredient suppliers limits the bargaining power of individual suppliers in this market.
Threat of new substitutes: Drugs targeting other pathways have emerged as substitutes for P2Y12 inhibitors to some extent.
Competitive rivalry: Major companies aggressively compete to gain market share in this market.
Geographical Regions
The Northeast region accounts for the largest share of the U.S. P2Y12 inhibitors market in terms of value due to a high number of pharmaceutical companies and research organizations located in states like New Jersey and Pennsylvania.
The Western region is expected to grow at the fastest pace during the forecast period. This can be attributed to expansion strategies adopted by major players and increasing research initiatives in states like California and Washington.
For more details on the report, Read- https://www.rapidwebwire.com/u-s-p2y12-inhibitors-market-demand-share-analysis/
Comments
0 comment